France's SpineGuard 2025 revenue falls 19% on business model transformation

Spineguard SA

08/04/2026 06:10

Overview

France medical device maker's 2025 revenue fell 19% yr/yr, operating loss narrowed 46%

Q1 2026 sales declined 32% yr/yr, with US sales down 45% due to stocking effect

Company secured up to €1 mln in new bond financing, extending cash runway to Q2 2027

Outlook

SpineGuard aims to achieve operational breakeven by end-2026

Company says U.S. business model transformation is key to breakeven goal

Pending sale of SpineGuard Inc. to Omnia Medical remains subject to closing conditions

Result Drivers

US BUSINESS MODEL TRANSFORMATION - Co said lower 2025 revenue and US sales reflect ongoing shift in US business model with Omnia Medical

COST SAVINGS - Co attributed improved operating income to lower sales, marketing, administrative, and technical expenses, as well as reduced executive compensation

STOCKING EFFECT - Co said Q1 2026 US sales were negatively impacted by a stocking effect in preparation of the transfer of SpineGuard Inc.

Company press release: ID:nBwqKdZza

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Sales
EUR 1 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Spineguard SA is €0.43, about 257.7% above its April 7 closing price of €0.12

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)